Increased potentiation of 5-fluorouracil induced thymidylate synthase inhibition by 5,10-methylenetetrahydrofolate (arfolitixorin) compared to leucovorin in patients with colorectal liver metastases; The Modelle-001 Trial

被引：0
|
作者：
Helena Taflin [1 ]
Elisabeth Odin [2 ]
Göran Carlsson [1 ]
Bengt Gustavsson [2 ]
Oskar Hemmingsson [1 ]
Yvonne Wettergren [2 ]
Krzysztof Urbanowicz [1 ]
Jacek Turyn [2 ]
Ryszard T. Smolenski [3 ]
Godefridus J. Peters [1 ]
机构：
[1] University of Gothenburg,Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy
[2] Department of Surgery,Region Västra Götaland, Sahlgrenska University Hospital
[3] Umeå University,Department of Diagnostics and Intervention/Surgery
[4] Medical University of Gdansk,Department of Biochemistry
[5] Vrije Universiteit Amsterdam,Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers (Amsterdam UMC)
来源：
BJC Reports | / 2卷 / 1期
关键词：
D O I：
10.1038/s44276-024-00111-4
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 38 条
  • [31] SAFETY AND EFFICACY OF INTRAVENOUS CETUXIMAB (CET) AND HEPATIC ARTERY INFUSION OF IRINOTECAN, 5-FLUOROURACIL AND OXALIPLATIN IN PATIENTS WITH UNRESECTABLE LIVER METASTASES FROM WT KRAS COLORECTAL CANCER (CRC): RESULTS FROM OPTILIV EUROPEAN PHASE II TRIAL
    Levi, F.
    Boige, V.
    Rougier, P.
    Hebbar, M.
    Smith, D.
    Focan, C.
    Guimbaud, R.
    Carvalho, C.
    Bouchahda, M.
    Ducreux, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 194 - 194
  • [32] Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: Long-term results of a phase II trial
    Boxberger, Frank
    Albrecht, Heinz
    Konturek, Peter
    Reulbach, Udo
    Maennlein, Gudrun
    Meyer, Thomas
    Hohenberger, Werner
    Hahn, Eckhart G.
    Wein, Axel
    MEDICAL SCIENCE MONITOR, 2010, 16 (02): : CR49 - CR55
  • [33] Safety and efficacy of neoadjuvant combination of hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil, and oxaliplatin with intravenous (iv) cetuximab in patients with unresectable liver metastases from colorectal cancer (CRC): Interim report from OPTILIV-A European multicenter phase II trial.
    Ducreux, M.
    Rougier, P.
    Smith, D.
    Focan, C. N. J.
    Innominato, P. F.
    Bouchahda, M.
    Ajavon, Y.
    Castaing, D.
    De Baere, T.
    Karaboue, A.
    Lepere, C.
    Boige, V.
    Adam, R.
    Levi, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] First European phase II trial of intravenous (iv) cetuximab (Cet) and hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin in patients with unresectable liver metastases from wt KRAS colorectal cancer (CRC) after systemic therapy failure (OPTILIV, NCT00852228)
    Levi, Francis
    Ducreux, Michel
    Hebbar, Mohamed
    Rougier, Philippe
    Focan, C. N. J.
    Guimbaud, Rosine
    Carvalho, Carlos
    Tumolo, Salvatore
    Innominato, Pasquale F.
    Ajavon, Yves
    Castaing, Denis
    De Baere, Thierry
    Karaboue, Abdoulaye
    Lepere, Celine
    Boige, Valerie
    Proux, Laetitia
    Adam, Rene
    Bouchahda, Mohamed
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Chronomodulated hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil (5-FU), and oxaliplatin (l-OHP) plus intravenous (iv) cetuximab (Cet) (Chrono-Optiliv) in patients with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after treatment failure (European Phase II trial NCT 00852228)
    Bouchahda, Mohamed
    Karaboue, Abdoulaye
    Etienne-Grimaldi, Marie-Christine
    Chatelut, Etienne
    Innominato, Pasquale F.
    Paintaud, Gilles
    Ricca, Luana
    Vibert, Eric
    Ajavon, Yves
    Awad, Sameh
    Castaing, Denis
    Focan, C. N. J.
    Milano, Gerard
    Morere, Jean Francois
    Adam, Rene
    Levi, Francis
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] Final results of first European phase II trial of intravenous cetuximab (Cet) and hepatic artery infusion of irinotecan, 5-fluorouracil, and oxaliplatin in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after systemic treatment failure (OPTILIV, NCT00852228).
    Levi, Francis
    Boige, Valerie
    Hebbar, Mohamed
    Smith, Denis
    Lepere, Celine
    Focan, C. N. J.
    Guimbaud, Rosine
    Carvalho, Carlos
    Tumolo, Salvatore
    Innominato, Pasquale F.
    Ajavon, Yves
    Truant, Stephanie
    Castaing, Denis
    De Baere, Thierry
    Kunstlinger, Francis
    Karaboue, Abdoulaye
    Bouchahda, Mohamed
    Rougier, Philippe R.
    Adam, Rene
    Ducreux, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [37] Hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil, and oxaliplatin plus intravenous cetuximab (Cet) (Optiliv) after failure on one versus two or three chemotherapy protocols in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) (European phase II clinical trial NCT00852228).
    Ducreux, Michel
    Innominato, Pasquale F.
    Hebbar, Mohamed
    Smith, Denis Michel
    Lepere, Celine
    Focan, C. N. J.
    Guimbaud, Rosine
    Carvalho, Carlos
    Tumolo, Salvatore
    Awad, Sameh
    Truant, Stephanie
    Castaing, Denis
    Karaboue, Abdoulaye
    De Baere, Thierry
    Kunstlinger, Francis
    Bouchahda, Mohamed
    Boige, Valerie
    Rougier, Philippe
    Adam, Rene
    Levi, Francis
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Early tumor shrinkage as a predictor for long-term outcome in patients (pts) with unresectable liver metastases from wt-KRAS colorectal cancer (LM-CRC) treated with hepatic artery infusion (HAI) of Irinotecan, 5-Fluorouracil and Oxaliplatin plus intravenous Cetuximab (IV-Cet) after failure of one to three systemic protocols (European phase II clinical trial NCT00852228)
    Bouchahda, M.
    Michel, D.
    Denis, S.
    Abdoulaye, K.
    Mohamed, H.
    Celine, L.
    Christian, F.
    Rosine, G.
    Pasquale, I.
    Sameh, A.
    Carlos, C.
    Salvatore, T.
    Stephanie, T.
    Thierry, D. B.
    Denis, C.
    Philippe, R.
    Valerie, B.
    Francois, M. Jean
    Rene, A.
    Francis, L.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S348 - S348
1234